[
    "{\"step_by_step_thinking\": \"Istiratumab is an experimental monoclonal antibody for the treatment of cancer, including pancreatic cancer. However, according to the results of a phase II study, istiratumab failed to improve the efficacy of standard of care chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma. Therefore, based on the current evidence, it should not be used for pancreatic cancer.\", \"answer_choice\": \"B. no\"}"
]